metastatic renal cell carcinoma: a guide to therapy based on current evidence

Clicks: 304
ID: 202400
2009
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #16 of 60 articles by views in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Metastatic renal cell carcinoma (RCC) was, until recently, considered a challenging disease to treat with few therapeutic options of limited benefit. The past few years have seen spectacular advances in the treatment of this disease based on understanding the molecular pathways behind tumor growth and angiogenesis. This progress has led to the development of targeted therapies such as the receptor tyrosine kinase inhibitors sunitinib and sorafenib, the anti-vascular endothelial growth factor antibody bevacizumab, and a class of rapamycin analogues that includes temsirolimus and everolimus that have each demonstrated clinical efficacy in patients with metastatic RCC. The goal of this manuscript is to review the current evidence based on large randomized trials and propose a rationale paradigm for the treatment of this disease.
Reference Key
toni2009urologymetastatic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Choueiri Toni
Journal European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Year 2009
DOI
DOI not found
URL
http://www.urologyannals.com/article.asp?issn=0974-7796;year=2009;volume=1;issue=1;spage=9;epage=14;aulast=Choueiri
Keywords
everolimus renal cell carcinoma sorafenib mammalian target of rapamycin vascular endothelial growth factor bevacizumab temsirolimus urology <i> von hippel-lindau</i>diseases of the genitourinary system

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.